Phase 2b/3 Trial of NuSepin® in COVID-19 Pneumonia Patients

PHASE2/PHASE3UnknownINTERVENTIONAL

Enrollment

1,134

Participants

Timeline

Start Date

April 12, 2022

Primary Completion Date

November 30, 2024

Study Completion Date

December 31, 2024

Conditions

COVID-19 Pneumonia

Interventions

DRUG

NuSepin® 0.2 mg/kg

NuSepin® 0.2 mg/kg in 100mL NS bid

DRUG

NuSepin® 0.4 mg/kg

NuSepin® 0.4 mg/kg in 100mL NS bid

DRUG

Placebo

Normal saline (NS) 100mL bid

Trial Locations (1)

RECRUITING

Gachon University Gil Medical Center, Incheon